{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:38:36Z","timestamp":1792726716724,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.tjpad.2026.100531","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T13:42:38Z","timestamp":1773409358000},"page":"100531","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Validation of a novel cognitive-functional outcome measure optimized for early Alzheimer\u2019s Disease: Evidence from the VIVA-MIND trial"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-5962-1110","authenticated-orcid":false,"given":"Jasmin A.","family":"Duehring","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane M.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4533-4090","authenticated-orcid":false,"given":"David P.","family":"Salmon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"MacKelfresh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Revta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schaeffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Schell-Mader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Wassmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Wenzkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9258-4538","authenticated-orcid":false,"given":"Howard H.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1153-7335","authenticated-orcid":false,"given":"Steven D.","family":"Edland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.tjpad.2026.100531_bib0001","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s Disease","volume":"388","author":"Van Dyck","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.tjpad.2026.100531_bib0002","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.tjpad.2026.100531_bib0003","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of Aducanumab in early Alzheimer\u2019s Disease","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2026.100531_bib0004","series-title":"Early Alzheimer\u2019s Disease: developing drugs for treatment; guidance for industry","year":"2018"},{"key":"10.1016\/j.tjpad.2026.100531_bib0005","series-title":"Early Alzheimer\u2019s Disease: developing drugs for treatment; guidance for industry","year":"2024"},{"key":"10.1016\/j.tjpad.2026.100531_bib0006","unstructured":"European Medicines Agency. Leqembi: EPAR - product information. 2025."},{"key":"10.1016\/j.tjpad.2026.100531_bib0007","unstructured":"European Medicines Agency. Kisunla: EPAR - product information. 2025."},{"issue":"5","key":"10.1016\/j.tjpad.2026.100531_bib0008","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1007\/s00259-025-07066-9","article-title":"Lecanemab approval in EU: what should we be ready for?- the EANM perspective","volume":"52","author":"Yakushev","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"10.1016\/j.tjpad.2026.100531_bib0009","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70652","article-title":"Real-world lecanemab adoption in Japan 1 year after launch: insights from 311 specialists on infrastructure and reimbursement barriers","volume":"21","author":"Sato","year":"2025","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2026.100531_bib0010","series-title":"Early Alzheimer\u2019s Disease: developing drugs for treatment; guidance for industry","year":"2013"},{"issue":"20","key":"10.1016\/j.tjpad.2026.100531_bib0011","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1056\/NEJMoa2304430","article-title":"Two phase 3 trials of Gantenerumab in early Alzheimer\u2019s Disease","volume":"389","author":"Bateman","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100531_bib0012","article-title":"The HOPE4MCI study: a randomized double-blind assessment of AGB101 for the treatment of MCI due to AD","volume":"10","author":"Mohs","year":"2024","journal-title":"Alzheimers Dement Transl Res Clin Interv"},{"issue":"1S","key":"10.1016\/j.tjpad.2026.100531_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.jalz.2011.11.002","article-title":"Rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer\u2019s Disease clinical trials","volume":"9","author":"Cedarbaum","year":"2013","journal-title":"Alzheimers Dement"},{"issue":"6","key":"10.1016\/j.tjpad.2026.100531_bib0014","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.jalz.2011.01.005","article-title":"Suitability of the Clinical Dementia Rating-Sum of Boxes as a single primary endpoint for Alzheimer\u2019s Disease trials","volume":"7","author":"Coley","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"2","key":"10.1016\/j.tjpad.2026.100531_bib0015","doi-asserted-by":"crossref","first-page":"151","DOI":"10.14283\/jpad.2020.73","article-title":"Psychometric properties of the clinical dementia rating - sum of boxes and other cognitive and functional outcomes in a prodromal Alzheimer\u2019s Disease population","volume":"8","author":"McDougall","year":"2021","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100531_bib0016","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000089218","article-title":"The clinical dementia rating sum of box score in mild dementia","volume":"21","author":"Lynch","year":"2006","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"8","key":"10.1016\/j.tjpad.2026.100531_bib0017","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1001\/archneur.65.8.1091","article-title":"Staging dementia using clinical dementia rating scale sum of boxes scores: a Texas Alzheimer\u2019s Research Consortium Study","volume":"65","author":"O\u2019Bryant","year":"2008","journal-title":"Arch Neurol"},{"issue":"1S","key":"10.1016\/j.tjpad.2026.100531_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.jalz.2012.01.005","article-title":"Progression of Alzheimer\u2019s Disease as measured by Clinical Dementia Rating Sum of Boxes scores","volume":"9","author":"Williams","year":"2013","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2026.100531_bib0019","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.705782","article-title":"Operational determination of subjective cognitive decline, mild cognitive impairment, and dementia using sum of boxes of the clinical dementia rating scale","volume":"13","author":"Yang","year":"2021","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100531_bib0020","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13195-021-00832-5","article-title":"Using historical data to facilitate clinical prevention trials in Alzheimer disease? An analysis of longitudinal MCI (mild cognitive impairment) data sets","volume":"13","author":"Berres","year":"2021","journal-title":"Alzheimers Res Ther"},{"issue":"1S","key":"10.1016\/j.tjpad.2026.100531_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.jalz.2012.05.2187","article-title":"The ADAS-Cog revisited: novel composite scales based on ADAS-Cog to improve efficiency in MCI and early AD trials","volume":"9","author":"Raghavan","year":"2013","journal-title":"Alzheimers Dement"},{"issue":"5","key":"10.1016\/j.tjpad.2026.100531_bib0022","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/pst.1701","article-title":"Optimal composite scores for longitudinal clinical trials under the linear mixed effects model","volume":"14","author":"Ard","year":"2015","journal-title":"Pharm Stat"},{"issue":"9","key":"10.1016\/j.tjpad.2026.100531_bib0023","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1001\/archneur.64.9.1323","article-title":"A neuropsychological test battery for use in Alzheimer disease clinical trials","volume":"64","author":"Harrison","year":"2007","journal-title":"Arch Neurol"},{"issue":"8","key":"10.1016\/j.tjpad.2026.100531_bib0024","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamaneurol.2014.803","article-title":"The preclinical Alzheimer Cognitive Composite: measuring amyloid-related decline","volume":"71","author":"Donohue","year":"2014","journal-title":"JAMA Neurol"},{"issue":"s1","key":"10.1016\/j.tjpad.2026.100531_bib0025","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.3233\/JAD-231126","article-title":"Varoglutamstat: inhibiting glutaminyl cyclase as a novel target of therapy in early Alzheimer\u2019s Disease. Moreira PI","volume":"101","author":"Feldman","year":"2024","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"10.1016\/j.tjpad.2026.100531_bib0026","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer\u2019s Disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s Disease","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"3","key":"10.1016\/j.tjpad.2026.100531_bib0027","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s Disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s Disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2026.100531_bib0028","doi-asserted-by":"crossref","unstructured":"Feldman H.H., Messer K., MacKelfresch A.J., Zhang J., Quach N.E., Edland S.D., et al. The VIVA-MIND study: topline results from phase 2 RCT of Varoglutamstat in early AD [poster]. Presented at: Alzheimer\u2019s Association International Conference; 2025 Jul 27-31; Toronto, Canada. In.","DOI":"10.1002\/alz70859_105693"},{"issue":"9","key":"10.1016\/j.tjpad.2026.100531_bib0029","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1136\/jnnp-2015-312383","article-title":"ADCOMS: a composite clinical outcome for prodromal Alzheimer\u2019s Disease trials","volume":"87","author":"Wang","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100531_bib0030","article-title":"Development of a novel cognitive composite outcome to assess therapeutic effects of exercise in the EXERT trial for adults with MCI: the ADAS-Cog-Exec","volume":"6","author":"Jacobs","year":"2020","journal-title":"Alzheimers Dement Transl Res Clin Interv"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100531_bib0031","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1515\/ijb-2020-0107","article-title":"Power formulas for mixed effects models with random slope and intercept comparing rate of change across groups","volume":"18","author":"Zhao","year":"2022","journal-title":"Int J Biostat"},{"issue":"s3","key":"10.1016\/j.tjpad.2026.100531_bib0032","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3233\/JAD-2011-0062","article-title":"Power calculations for clinical trials in Alzheimer\u2019s Disease","volume":"26","author":"Ard","year":"2011","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2026.100531_bib0033","series-title":"Analysis of longitudinal data. 2nd editor","first-page":"379","year":"2002"},{"issue":"3","key":"10.1016\/j.tjpad.2026.100531_bib0034","doi-asserted-by":"crossref","first-page":"937","DOI":"10.2307\/2533554","article-title":"Sample size calculations for studies with correlated observations","volume":"53","author":"Liu","year":"1997","journal-title":"Biometrics"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100531_bib0035","doi-asserted-by":"crossref","first-page":"264","DOI":"10.32614\/RJ-2022-022","article-title":"Power and sample size for longitudinal models in R \u2013 the longpower package and shiny app","volume":"14","author":"Iddi","year":"2022","journal-title":"R J"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100531_bib0036","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.trci.2017.12.002","article-title":"A simulation study comparing slope model with mixed-model repeated measure to assess cognitive data in clinical trials of Alzheimer\u2019s Disease","volume":"4","author":"Chen","year":"2018","journal-title":"Alzheimers Dement Transl Res Clin Interv"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100531_bib0037","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13195-022-00984-y","article-title":"Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer\u2019s Disease","volume":"14","author":"Assun\u00e7\u00e3o","year":"2022","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100531_bib0038","doi-asserted-by":"crossref","first-page":"9","DOI":"10.14283\/jpad.2022.102","article-title":"Establishing clinically meaningful change on outcome assessments frequently used in trials of mild cognitive impairment due to Alzheimer\u2019s Disease","volume":"10","author":"Lansdall","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"issue":"3","key":"10.1016\/j.tjpad.2026.100531_bib0039","article-title":"Clinically meaningful changes in cognitive and functional outcomes in a population-based study of cognitive aging","volume":"11","author":"Aakre","year":"2025","journal-title":"Alzheimers Dement Transl Res Clin Interv"},{"issue":"5","key":"10.1016\/j.tjpad.2026.100531_bib0040","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1002\/alz.13770","article-title":"Minimal clinically important difference in Alzheimer\u2019s Disease: rapid review","volume":"20","author":"Muir","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100531_bib0041","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.trci.2019.06.005","article-title":"Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer\u2019s Disease clinical trials","volume":"5","author":"Andrews","year":"2019","journal-title":"Alzheimers Dement Transl Res Clin Interv"},{"issue":"3","key":"10.1016\/j.tjpad.2026.100531_bib0042","doi-asserted-by":"crossref","first-page":"507","DOI":"10.14283\/jpad.2022.41","article-title":"Clinical trial endpoints and their Clinical meaningfulness in early stages of Alzheimer\u2019s Disease","volume":"9","author":"Cohen","year":"2022","journal-title":"J Prev Alzheimers Dis"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580726000555?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580726000555?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:03:17Z","timestamp":1792724597000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580726000555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2274580726000555"],"URL":"https:\/\/doi.org\/10.1016\/j.tjpad.2026.100531","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Validation of a novel cognitive-functional outcome measure optimized for early Alzheimer\u2019s Disease: Evidence from the VIVA-MIND trial","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjpad.2026.100531","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS on behalf of SERDI Publisher.","name":"copyright","label":"Copyright"}],"article-number":"100531"}}